Table I.
Characteristics of dermatologic vaccine reactions reported after COVID-19 vaccination to the AAD/ILDS COVID-19 Dermatology Registry∗
| Moderna dose 1 | Moderna dose 2 | Pfizer dose 1 | Pfizer dose 2 | Astrazeneca dose 1 | Astrazeneca dose 2 | Johnson & Johnson | Sputnik V dose 1 | Sputnik V dose 2 | Sinovac-Coronavac dose 1 | Sinovac-Coronavac dose 2 | Unknown dose 1 | Unknown dose 2 | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of individuals | 427 | 214 | 114 | 140 | 9 | 2 | 11 | 0 | 1 | 3 | 1 | 19 | 21 | 870 |
| Patient age (Median, IQR) | 49 (37-66) | 47 (37-61) | 46 (35-56) | 51 (37-64) | 49 (44.5-55.5) | 39.5 (37-42) | 51 (28-60) | - | 38 | 42 (19-85) | 42 | 61 (45-75) | 60 (49-75) | - |
| Patient sex (F) | 366 (85.7%) | 181 (84.5%) | 77 (67.5) | 103 (73.6%) | 5 (55.5%) | 1 (50%) | 10 (90.9%) | - | 0 (0) | 3 (100%) | 1 (100%) | 16 (84.2%) | 13 (61.9%) | 776 (89.2%) |
| Number of vaccine reactions | 998 | 526 | 208 | 228 | 22 | 2 | 15 | 0 | 2 | 3 | 1 | 27 | 31 | 2063 |
| Local reactions | ||||||||||||||
| Local swelling | 151 | 97 | 12 | 14 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 281 |
| Local erythema | 169 | 101 | 13 | 15 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 307 |
| Local pain | 116 | 81 | 14 | 14 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 231 |
| Delayed local hypersensitivity reaction | 230 | 50 | 12 | 17 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 314 |
| Distal and/or generalized reactions | ||||||||||||||
| Pruritus | 138 | 64 | 23 | 25 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 5 | 3 | 263 |
| Urticaria | 28 | 22 | 24 | 21 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 101 |
| Morbilliform | 26 | 17 | 16 | 15 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 81 |
| Zoster | 19 | 5 | 11 | 13 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 4 | 4 | 59 |
| Vesicular | 14 | 8 | 11 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47 |
| Pityriasis rosea | 10 | 6 | 3 | 5 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 31 |
| Pernio/chilblains | 7 | 3 | 5 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 26 |
| Erythema multiforme | 13 | 3 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 24 |
| Bullous disease | 7 | 1 | 5 | 9 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 23 |
| Erythromelalgia | 7 | 7 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 |
| Filler reaction | 7 | 7 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 |
| Angioedema | 6 | 5 | 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 |
| Contact dermatitis | 5 | 3 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 14 |
| Vasculitis | 3 | 1 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 11 |
| Alopecia | 1 | 2 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 9 |
| Petechiae | 1 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Reaction in breast-fed infant | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Livedo reticularis | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| New dermatologic condition | 7† | 3‡ | 1§ | 8‖ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2¶ | 21 |
| Flare of existing dermatologic condition | 9 | 13 | 15 | 9 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 49 |
| Other | 24 | 23 | 20 | 23 | 2 | 1 | 3 | 0 | 0 | 1 | 0 | 1 | 2 | 100 |
F, Female; IQR, interquartile range.
∗
December 24, 2020—August 16, 2021.
†
Moderna first dose: lichen planus (4); psoriasis (1); possible leukocytoclastic vasculitis (1); Acne vulgaris (1).
‡
Moderna second dose: granuloma annulare (1); lichen planus (1); psoriasis (1).
§
Pfizer first dose: herpes zoster (1).
‖
Pfizer second dose: lichen planus (2), granuloma annulare (1), morphea (1), Raynaud (1), pityriasis lichenoides (1); “lichen striatus versus inflammatory linear verrucous epidermal nevus versus Wolf isotopic response” (1); unspecified toe rash (1).
¶
Unknown second dose: granuloma annulare (1); sarcoidosis (1).